Study of 4 drugs for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of four drugs for people with advanced colorectal cancer who have already tried at least two other treatments. The goal is to see if this new mix can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced colorectal cancer that has spread or cannot be removed by surgery.
- You have already tried at least two standard treatments and they stopped working or caused side effects.
- You have at least one tumor that can be measured on a scan.
- You are 18 years or older and in generally good health (able to do daily activities).
- Your kidney and liver function must be within certain limits as shown on blood tests.
- You are not pregnant and agree to use birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (irinotecan liposomes, cetuximab, and vemurafenib) for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E mutation) and did not respond to first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two drugs (cadonilimab plus regorafenib) as a possible third-line option for people with colorectal cancer that has spread to the liver. It is for patients whose cancer is the MSS/pMMR type and who have already tried standard treatments without success.
This trial tests a combination of two drugs (cadonilimab and an anti-angiogenic agent) for advanced colorectal cancer that has a specific genetic feature (dMMR or MSI-H). It aims to find a new treatment option that might work better than current therapies.
This trial tests a combination of two drugs (ONGERICIMAB and TORIPALIMAB) for people with a specific type of colorectal cancer that did not respond to first treatment. It aims to see if this new approach can help shrink or control the cancer.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus bevacizumab (a targeted therapy) and alternating chemotherapy regimens as a first treatment for advanced colorectal cancer that cannot be removed by surgery. It aims to see if this combination is safe and effective.
This study is looking at how well a combination of medications works for people with advanced colorectal cancer that is microsatellite stable (MSS). The medications include chidamide, a PD-(L)1 inhibitor (a type of immunotherapy), and anti-angiogenic therapy (a treatment that blocks blood vessel growth to tumors).
Hear when a new Advanced Colorectal Cancer in the Third-line Treatment and Beyond trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.